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To the Ministry of Social Affairs and Health 
 
 
 
 
 
 
 
 
 
 
 
A steering group for rare diseases was appointed by the Ministry of Social Affairs and Health 
for the period 1 June 2012–31 December 2013.  
 
The objectives of the steering group were the following:  
1. Promoting the utilisation of the Finnish health care system's knowledge and 
experience for improving the lives of people with a rare disease 
2. Promoting research and equity in access to quality care 
3. Steering Finland’s activities in the European Union Committee of Experts on Rare 
Diseases (EUCERD) Joint Action and issues related to the implementation of the 
EU Directive on patients' rights cross-border healthcare. 
 
The steering group's tasks were to: 
1. Plan and direct the implementation of the Council Recommendation on action in 
the field of rare diseases in Finland 
2. Submit proposals concerning the monitoring of implemented actions and other 
measures that may be necessary. 
 
Steering group chairperson was Director Liisa-Maria Voipio-Pulkki from the Ministry of 
Social Affairs and Health. Vice chairperson of the steering group was General Secretary 
Päivi Topo from the National Advisory Board on Social Welfare and Health Care Ethics until 
4 February 2013, after which date this role was performed by Ministerial Counsellor Jaakko 
Yrjö-Koskinen from the Ministry of Social Affairs and Health. 
 
The appointed steering group members and their personal deputies (in brackets) were the 
following: 
‐ General Secretary Leila Jylhänkangas, National Advisory Board on Social Welfare and 
Health Care Ethics, took over from General Secretary Päivi Topo as from 31 May 2013 
‐ Ministerial Adviser Pälvi Kaukonen, Member until 6 November 2012, was substituted by 
Ministerial Counsellor Jaakko Yrjö-Koskinen, both from the Ministry of Social Affairs 
and Health  
‐ Director Annakaisa Iivari, Member until 20 March 2013, was substituted by Senior 
Medical Officer Teppo Heikkilä, both from the Ministry of Social Affairs and Health 
‐ Ministerial Adviser Jaana Huhta, Ministry of Social Affairs and Health (Ministerial 
Adviser Anne-Mari Raassina) 
‐ Research Professor Helena Kääriäinen, National Institute for Health and Welfare (Head of 
Unit Jukka Kärkkäinen)  
‐ Chief Administrative Physician Päivi Koivuranta-Vaara, Association of Finnish Local and 
Regional Authorities (Development Manager Heikki Punnonen)  
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‐ Chief Physician, Paediatric Neurology Pirkko Karttunen-Lewandowski, Etelä-Savo 
Hospital District Joint Municipal Authority (Medical Director Matti Suistomaa) 
‐ Chief Physician Leila Saulamaa, Pirkanmaa Hospital District (Paediatrician Päivi 
Keskinen) 
‐ Chief Physician Markku Savolainen, Northern Ostrobothnia Hospital District  (Paediatric 
Neurologist Johanna Uusimaa) 
‐ Docent Harri Niinikoski, Southwest Finland Hospital District 
‐ Professor of Paediatrics Jarmo Jääskeläinen, Pohjois-Savo Hospital District (Professor of 
Clinical Epileptology Reetta Kälviäinen) 
‐ Neurologist Riitta Pirilä, Lapland Hospital District (Paediatric Neurologist Laura 
Simontaival) 
‐ Head of Nursing Leena Vekara, City of Tampere (Head Nurse Anja  
Jalonen-Männikkö) 
‐ Senior Social Worker Emmi Hanhikoski, City of Jyväskylä 
‐ Specialist, Plastic Surgery Jorma Rautio, Hospital District of Helsinki and Uusimaa,  the 
Cleft Palate and Craniofacial Centre (Specialist, Internal Medicine Ilkka Kantola) 
‐ Docent Sirkku Peltonen, Turku University Central Hospital (Professor Anna-Elina 
Lehesjoki) 
‐ Docent Risto Lapatto, Helsinki University Central Hospital, Gynaecological and 
Paediatric profit centre 
‐ Chief Physician Niilo Keränen, Kuusamo Health Centre, member of the National 
Network of Public Health Care Managers  
‐ Chief Physician Riitta Salonen-Kajander, Rinnekoti Foundation (Specialist in Genetics 
Kristiina Avela, and as from 20 March 2013, Informatician Leena Toivanen, both from 
Rinnekoti Foundation)  
‐ Board Member Katri Karlsson, Harso Association (Board Member Päivi Reinikka, Harso 
Association)  
‐ Senior Planning Officer Eila Niemi, the Finnish MS Society / the Finnish Network for 
Rare Diseases (Development Manager Jaana Hirvonen, the Finnish Rheumatism 
Association / the Finnish Network for Rare Diseases) 
‐ Chairperson Jukka Sariola, the Finnish Neuromuscular Disorders Association / the Finnish 
Network for Rare Diseases (Jussi Lindevall, DebRA Finland / the Finnish Network of 
Rare Diseases) 
 
On 18 October 2012, Ministerial Counsellor Ulla Närhi from the Ministry of Social Affairs 
and Health and Research Professor Ilona Autti-Rämö from Social Insurance Institution's 
research division were appointed to the steering group as additional members.  
The steering group met nine times. Two working groups were set up to prepare the 
National Plan and a seminar focusing on it and to draw up proposals for the centre of expertise 
selection process. On 18–19 March 2013, the steering group organised a seminar in Hanasaari 
Cultural Centre to engage stakeholders in the preparation of the National Plan. A total of 78 
stakeholder representatives, of whom 29 were from patient organisations, took part in the 
seminar. The steering group consulted Docent Jaana Lähdetie from Turku University Central 
Hospital and Director Jarmo Wahlfors from the Academy of Finland.  
The Ministry of Social Affairs and Health concluded service contracts with Katja Aktan-
Collan (16 April–31 December 2012) and Elina Rantanen (3 April–30 December 2013) on 
providing assistance in the preparation of the National Plan under the direction of the steering 
group. 
In October 2013, the steering group requested feedback on the Draft National Plan from its 
members' background organisations. The feedback received was taken into consideration in 
the final version of the National Plan. 
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The steering group submits its proposal to the Ministry of Social Affairs and Health and 
urges the Ministry to initiate the requisite further measures to implement the National Plan for 
Rare Diseases.   
 
 
Helsinki, 13 March 2014 
 
 
 
 
   Liisa-Maria Voipio-Pulkki      Jaakko Yrjö-Koskinen 
 
 
 
Leila Jylhänkangas Teppo Heikkilä  Jaana Huhta 
 
 
 
Ulla Närhi  Helena Kääriäinen Ilona Autti-Rämö 
 
 
 
Päivi Koivuranta-Vaara Pirkko Karttunen-Lewandowski 
 
 
 
Leila Saulamaa  Markku Savolainen  Harri Niinikoski 
 
 
 
Jarmo Jääskeläinen Riitta Pirilä  Leena Vekara 
 
 
 
Emmi Hanhikoski Jorma Rautio  Sirkku Peltonen 
 
 
 
Risto Lapatto  Niilo Keränen   Riitta Salonen-Kajander 
 
 
 
Katri Karlsson  Eila Niemi  Jukka Sariola 
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1  INTRODUCTION 
 
The European Union's definition of a rare disease is a disease affecting no more than 5 per 
10 000 persons. It is estimated that over 300 000 Finnish people are affected by a rare disease, 
disability, syndrome or malformation. They account for some six per cent of the population 
and a considerably larger share of major users of healthcare services. It is thus justified to take 
people with a rare disease into consideration as a specific group in the act on the arrangement 
of social welfare and health care services and in the development of the service structure. 
Living with a rare disease is associated with challenges encountered in the identification and 
care of diseases and disabilities, habilitation, services and everyday life.  The rarer the disease 
or disability, the more challenging it may be to find information and assistance. Plenty of 
resources are misspent when finding a correct diagnosis and suitable care takes an excessively 
long period of time. With the same expenditure of resources, the disease could be diagnosed 
and care could be provided much better and faster. 
In the National Plan, the concepts rare disease and people living with a rare disease are 
used to describe the similar problems encountered by people with a rare disease and actions 
taken to solve these problems. There are thousands of different rare diseases. At least 5 000 
have been discovered, and new ones are continuously being described in the literature. People 
living with a rare disease often share very similar problems, for example in receiving a correct 
diagnosis or finding appropriate information and expert specialist services.  Particular 
attention also needs to be paid to issues related to quality of care, access to medical and social 
support, and the effectiveness of care pathways between primary health care and specialised 
medical care. Aspects related to professional and social integration, independent coping, using 
ordinary services and managing everyday routines are also highlighted in the lives of people 
with a rare disease and their families. Peer support is less readily available for them than for 
other patient groups, and they are more exposed to psychological, social and financial 
problems.  
The Council of the European Union issued a recommendation on an action in the field of 
rare diseases in 2009 (Appendix 1). The recommendation notes that the principles and 
overarching values of universality, access to good quality care, equity and solidarity, as 
endorsed in the Council conclusions on common values and principles in EU health systems 
of 2 June 2006, are of paramount importance for patients with rare diseases. The Member 
States are urged to elaborate their plans and strategies in the field of rare diseases. A national 
plan in the field of rare diseases should be elaborated and adopted by the end of 2013 at the 
latest. The objective of the EU is to establish centres of expertise for rare diseases and to 
create networks for sharing expertise. 
A steering group on rare diseases was appointed by the Ministry of Social Affairs and 
Health for the period 1 June 2012─31 December 2013 and tasked to draw up Finland's 
National Plan for Rare Diseases. The steering group had the following objectives: 
1. Promote the use of knowledge and experience in the Finnish healthcare system for 
the benefit of patients with rare diseases. 
2. Promote research and equity in access to quality care 
3. Steer Finland’s activities in the European Union Committee of Experts on Rare 
Diseases (EUCERD) Joint Action and issues related to the implementation of the 
EU Directive on patients' rights in cross-border healthcare. 
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The steering group was tasked with the following: 
1. Plan and direct the implementation of the Council Recommendation on action in 
the field of rare diseases in Finland. 
2. Submit proposals concerning the monitoring of implemented actions and other 
measures that may be necessary. 
 
The steering group appointed two working groups among its members to plan the drafting 
of the National Plan and to consider the establishment of centres of expertise. A seminar on 
the National Plan for Rare Diseases was organised on 18–19 March 2013 to support plan 
preparation. At this seminar, the participants were divided into groups whose task was to 
identify requisite actions in the following areas of the National Plan: research in rare diseases, 
disease classification systems and registries of rare diseases, national definition and diagnosis 
of rare diseases, improvement of care and access to drugs, national centres of expertise, 
developing social support and the empowerment of people living with rare disease, as well as 
implementation, coordination, monitoring, evaluation, financing and international networking 
related to the national plan. A total of 78 representatives from various hospital districts, the 
Finnish Network for Rare Diseases and the HARSO network, the Social Insurance Institution, 
municipalities, the Finnish Slot Machine Association RAY and the Ministry of Social Affairs 
and Health attended the seminar. 
With financial support from EUROPLAN (European Project for Rare Diseases National 
Plans Development), the Finnish umbrella organisation for patients with rare diseases HARSO 
organised a conference in September 2013 that offered patient organisation representatives an 
opportunity to comment on the draft National Plan for Rare Diseases. This meeting was 
attended by 60 NGO representatives.  
The outcome of the above mentioned seminar provided the basis for drafting the National 
Plan for Rare Diseases. Feedback received from the participants to the conference hosted by 
HARSO and from the organizations that were represented in the steering group was taken into 
account in the finalisation of the plan. The plan aims to improve the quality of life for people 
living with a rare disease through their empowerment and by increasing the responsiveness of 
the Finnish health and social care system to their needs. People with a rare disease are entitled 
to the same quality of care and habilitation as other patients. A correct diagnosis, habilitation, 
medication and coping with everyday routines are essential elements of quality of life. Their 
value cannot be measured in monetary terms. Timely diagnosis of a rare disease and 
appropriate treatment and care also bring savings in health care expenditure. Expertise in 
diagnostics and care in the field of rare diseases is available in Finland, but it has not been put 
to effective use. The objective is to achieve better health outcomes by using available 
resources more efficiently. The plan aims to promote actions that are of high importance and 
have a real impact on the quality of life and well-being of people living with a rare disease. In 
this plan, the concept of rare diseases refers to rare diseases, disabilities, syndromes and 
malformations. 
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 2 FINLAND'S NATIONAL PLAN FOR 
 RARE DISEASES 
 
2.1 BACKGROUND ON THE FINNISH SITUATION 
 
While no National Plan for Rare Diseases has previously been prepared in Finland, rare 
diseases have been the object of increasing attention in the 1990s and 2000s. In 1991, the 
Ministry of Social Affairs and Health designated the Organisation of Respiratory Health in 
Finland, the Finnish Central Organisation for Skin Patients, the Finnish Association of People 
with Physical Disabilities, Inclusion Finland KVTL, the Federation of Hard of Hearing, the 
Finnish Federation of the Visually Impaired, the Rehabilitation Home for Children, the 
Finnish MS Society and the Finnish Rheumatism Association as resource centres for rare 
diseases. In 1995, the Finnish Network for Rare Diseases was set up, and its affiliated 
members included not only the organisations listed above but also other organisations in the 
field of social welfare and health working with patients with a rare disease.  
In spring 2012, HARSO Organisation for Rare Diseases and Disabilities in Finland was 
established as an umbrella organisation for people with a rare disease. Its members comprise 
22 national patient associations. HARSO strives to promote equal participation in society of 
people living with a rare disease and their families and better social and health care services 
for people with a rare disease. It also offers peer support for those whose disease is so rare that 
they have no dedicated patient organisation. 
National events on rare diseases are organised in Finland every year. The Orphanet team1 
collects and distributes information about expertise in the field of rare diseases. Health care 
system actors can access Orphanet information through Terveysportti health portal. A Nordic 
cooperation project was implemented in 2009−2010 with the purpose of sharing information 
and organising joint training events. While no centres of expertise for rare diseases have been 
designated in Finland so far, the university hospitals usually serve in this role, and some of 
them have expertise in certain diseases. The small population of the country and the Finnish 
diseases heritage set their own requirements to the National Plan for Rare Diseases and 
international cooperation. 
Finland's National Plan for Rare Diseases is influenced by many on-going national 
legislative reforms, including preparing the ratification of the UN Convention on the Rights of 
People with Disabilities and the setting up of a national Comprehensive Cancer Center. The 
framework for building up and sharing of expertise in the field of rare diseases is provided by 
the Health Care Act, the objective of which is to ensure equal access to quality health services 
and patient safety (Government decree 2011). The Health Care Act requires hospital districts 
within a catchment area for specialised medical care to agree upon the division of 
responsibilities and coordination (specialised medical care agreement). Some procedures and 
services that are deemed to constitute highly specialised medical care may be centralised.  
The increased freedom of choice affects the organisation of diagnostics and care in the field 
of rare diseases both on the national and the EU level. Under the Health Care Act the patient 
may, on certain conditions, choose a treatment facility anywhere in Finland as from 2014.  
The European context related to care in the field of rare diseases has been transformed by the 
Directive on the application of patients' rights in cross-border healthcare (2011) implemented 
in Finland from the beginning of 2014. Centres of expertise for rare diseases are needed in 
                                                 
1 Orphanet is an open European online service for rare diseases and orphan drugs. Its mission 
is to improve the diagnostics and care of rare diseases. 
12 
 
 
 
Finland to ensure optimal utilisation of national expertise; if patients seek care in other 
countries, this may prove significantly more expensive for them. 
The on-going reform of the social and health care service structure strives to contribute to 
guaranteeing equity in access to these services. The policies that set the course for this reform 
assign responsibility for organising social and health services to social welfare and health care 
regions. The tasks of the catchments areas for highly specialised medical care would include 
providing social and health care services specified as specialised level tasks, with the aim of 
eliminating overlaps in the service network and coordinating the activities regionally. An 
ownership structure that guarantees them adequate resources and an administrative solution 
that does not result in fragmentation of the functional whole has been proposed for university 
hospitals. Research, development and teaching are expected to have close links with service 
provision. The Government Bill on the arrangement of social welfare and health care services 
is to be submitted to the Parliament in spring 2014. 
The extent of and gaps in Finnish expertise in the field of rare diseases were surveyed by 
means of a questionnaire directed at chief physicians in specialised fields in university and 
central hospitals and the member organisations of the Finnish Network for Rare Diseases 
(Ministry of Social Affairs and Health 2011). The responses indicated a need for more 
cooperation in diagnostics and care in the field of rare diseases. In particular, the respondents 
called for more cooperation across administrative boundaries between hospital districts that 
would allow the sharing of responsibility for diagnostics, care and habilitation in the field of 
rare diseases between university hospitals. Various consultation networks were suggested as 
ways of addressing the existing shortcomings. While consultations are common today, the 
respondents would prefer a more clear-cut process based on agreements. The respondents also 
expressed a need for joint training and meetings where rare diseases could be discussed 
between different fields on the one hand, and between representatives of university hospitals 
and central hospitals on the other. They advocated centralisation, both within the special 
catchment areas and nationally. In addition to cooperation, there were shortcomings in 
knowledge and resources. The respondents called for training and clear instructions to 
eliminate gaps in knowledge. Lack of resources was seen to be particularly relevant to the 
numbers of physicians and their job descriptions: physicians cannot devote any more time to 
acquiring competence in rare diseases than in common diseases, even if more time is needed 
to acquire such competence in the field of rare diseases.  
A country-.specific study (2009) conducted by EURORDIS, an umbrella patient 
organisation for people with a rare disease, noted that people living with a rare disease in 
Finland had encountered shortcomings in access to information and care. One out of three 
Finnish respondents had been given a diagnosis without being appropriately informed of what 
the diagnosis means. 70% of the respondents were left without psychological support, even if  
91% felt that such support was important. 37% felt that accessing essential health services was 
difficult or impossible because these services did not exist, they were too expensive, the 
patient had not been referred to these services, the waiting times were excessive, or the 
services were too far away and difficult to reach.  
 
2.2 NATIONAL PLAN OBJECTIVES 
 
The steering group proposes the following goals for Finland's National Plan for Rare Diseases: 
 People with a rare disease will have access to services of the same quality as other 
patients 
 Preventive, diagnostic, care and habilitation services as well as social services required 
by people with a rare disease will be delivered to a high standard and equitably across 
the country 
 Units and centres of expertise for rare diseases will be set up 
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 Rare diseases will be diagnosed more promptly, and fewer patients will be left without 
a definitive diagnosis 
 Premature morbidity and mortality will be reduced 
 Multidisciplinary care will be better coordinated 
 Communication between professionals involved in the care of a patient will be 
improved, including during transitions from one care facility to another, or from 
paediatric to adult services 
 Healthcare resources in the field of rare diseases will be utilised more effectively 
 The quality of life and socio-economic situation of people living with a rare disease 
will improve 
 The availability of orphan drugs will be improved, and their costs to patients will be 
reimbursed more fully 
 Knowledge of rare diseases will be built up through research 
 Social welfare and health care professionals will have more extensive knowledge of 
rare diseases 
 Participation in international co-operation in the field of rare diseases will increase 
 Clearer cooperation channels will be created between experts, both nationally and 
internationally 
 People living with a rare disease and their families will be empowered to participate in 
decision-making in the field of rare diseases 
 The National Plan for Rare Diseases will be sustainably integrated into the Finnish 
social welfare and healthcare system 
 
The National Plan addresses the challenges posed by rare diseases in five areas. To respond 
to these challenges, the steering group proposes thirteen concrete actions that will promote the 
achievement of the aforementioned general objectives of the National Plan. In connection with 
each proposed action, indicators for monitoring progress, the responsible actor, a timeline and 
the prerequisites for successfully achieving the objective are set out. At the end of the plan 
document, the methodology for coordinating, monitoring and evaluating the implementation 
of the plan is described, and a summary of the actions is given in which priority areas are 
highlighted. 
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3 AREAS OF THE NATIONAL PLAN  
 
 3.1 AREA 1: DEFINITION AND REGISTRATION OF 
 RARE DISEASES 
 
The first step towards improving the care and quality of life of people with a rare disease is 
acknowledging their situation. Compared to the remainder of the population, people with a 
rare disease have poorer access to expert services. To guarantee people with a rare disease 
equality with those affected by more common diseases, dedicated measures are required in the 
service system. Even if each rare disease only affects a handful of people, the total number of 
patients is large: approximately six per cent of the adult population will be affected by a rare 
disease during their lives. In specialised medical care, the share of patients with a rare disease 
is significantly greater than this. 
A precondition for acknowledging the situation of people with a rare disease is adopting a 
uniform definition of rare diseases that enables to identify persons who are within the scope of 
dedicated measures required by rare diseases. As a result of inconsistencies in this definition at 
the EU level, problems arise in joint research projects and the sharing of expertise.  
Research and the dissemination of information are also hampered by a lack of databases on 
rare diseases. Since no data has been compiled in Finland on clinics treating rare diseases, on 
treatment practices, nor on research, the collection of information and exploitation of expertise 
are random and based on personal contacts. This prevents patients from accessing the best 
available expertise in diagnostics, care and habilitation.  
 
 3.1.1 Action 1: Adopting a uniform definition of rare diseases 
 and acknowledging the need for dedicated measures  
 
A definition of rare diseases will be adopted that is consistent with the EU definition. The need 
for dedicated measures targeted at rare diseases will be acknowledged in the legislation. 
 
The European Union recommendation proposes the implementation of a common 
identification of rare diseases by all the Member States, which would facilitate cooperation at 
Community level in the field of rare diseases. This National Plan uses the EU definition of 
rare diseases.  It defines as rare a disease affecting no more than 5 per 10 000 persons. In 
Finland, the EU definition means no more than 2 800 persons per each disease. In this plan 
document, rare diseases are understood in a broad sense to also comprise disabilities, 
malformations and syndromes. The plan seeks to respond to the challenge of rare diseases that 
are life-threatening or chronically debilitating. 
The majority of rare diseases have an extremely low prevalence. As the greatest challenges 
related to diagnostics and care are associated with these, the rarest of all diseases, they should 
be addressed separately in the National Plan implementation. It may be necessary to resort to 
international cooperation networks to seek expertise in these diseases.  
People living with a rare disease have the right to care of a similar quality that is available 
to other patients, and to social services that meet their specific needs. Because of their low 
prevalence and the scarcity of relevant expertise, rare diseases call for dedicated measures to 
ensure equal access to quality services. This has been the justification for European Union 
action in the field of rare diseases. This principle should be incorporated either in the new act 
on the arrangement of social and health care services or in its explanatory memorandum.  
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Objectives: 
 Defining rare diseases following the EU definition. 
 Acknowledging in the act on the arrangement of social welfare and health care 
services or its rationale that rare diseases necessitate dedicated measures in the 
service system. 
 
Indicator: Dedicated measures necessitated by rare diseases are referred to in the act or its 
rationale. 
 
Responsible actor: Ministry of Social Affairs and Health 
 
Timeline: The definition is introduced with immediate effect; the need for dedicated measures 
is acknowledged in the act on the arrangement of social welfare and health care services which 
is to enter into force in 2015, or in its rationale. 
 
Prerequisites: Political support 
 
 
3.1.2 Action 2: Registry of rare diseases 
 
A registry of rare diseases will be created as part of the current electronic Care Register for 
Health Care (Hilmo). For this purpose, a disease classification system that covers rare 
diseases more extensively than the current ICD-10 system must be introduced.  
 
Having a national registry of rare diseases in Finland is a precondition for developing both 
research and care. While systematic, data collection should be as automatic as possible; 
completing separate registration forms is labour-intensive and thus does not promote the 
collection of a comprehensive database. The compilation of registers should not entail 
additional work; a key feature of the registry is that it makes rare diagnoses more readily 
identifiable in the health care system. 
A separate national registry of rare diseases is not to be established in Finland. The 
registration of rare diseases will take place using the Care Register for Health Care (Hilmo) 
maintained by the National Institute for Health and Welfare. Finding rare diseases in the 
Hilmo register is the most crucial question in terms of following care pathways and 
disseminating epidemiological information. In the registry of rare diseases, an international 
diseases classification system will be used. This could be the ICD-11 system which, as far as 
is currently known, will include codes for a much wider spectrum of rare diseases than the 
current version. It is expected that ICD-11 will be in use by 2017. The actors responsible for 
maintaining health care registers in Finland should also take rare diseases into consideration 
when monitoring the development of codification systems and before making a decision on 
whether to wait for the completion of ICD-11 or whether some other disease classification 
system should be introduced in Finland before this date.  
 
In addition to an automated ICD registry, centres of expertise may compile their own registries 
of individual diseases. Patient consent must be obtained before registering patient data in 
them.  
 
Objectives: 
 People with a rare disease can be more readily identified. 
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 The possibility of identifying patient groups will facilitate the launching of 
research projects and improve opportunities for cooperation. 
 
Indicators: Codes for a much wider spectrum of rare diseases included in Hilmo 
 
Responsible actor: National Institute for Health and Welfare 
 
Timeline: Registry compilation will start at the latest when the ICD-11 classification system is 
introduced 
 
Prerequisites: Implementation of ICD-11 or introduction of some other disease codification 
system 
 
 
 3.2 AREA 2: RESEARCH IN THE FIELD OF RARE 
 DISEASES 
 
In the allocation of funds for research, research in the field of rare diseases may be overlooked 
in favour of more common diseases. It is difficult to collect sufficiently large patient data sets 
for clinical and epidemiological research because patient groups are small and due to the lack 
of registries and inadequate diagnostics. For the same reasons, research on the quality of life 
of people with a rare disease and on how they cope with it in their everyday lives is unable to 
compete for research funding. Development of treatments is driven by the pharmaceutical 
industry which is not interested in developing drugs for small patient groups as financial gains 
from this would be uncertain. Information on research projects has not been systematically 
complied. Researchers are thus missing out on the benefits of cooperation. However, since the 
development of social and health care services must be based on information, there is a need 
for research focussing on the services for people with a rare disease and on the impact of the 
services on their health, well-being and coping with everyday life.  
 
 3.2.1 Action 3: Research funding and a research programme 
 focusing on rare diseases 
 
A share of national research funding will be earmarked for research in rare diseases and the 
Finnish disease heritage. An initiative will be prepared and submitted to the Academy of 
Finland concerning the development of a multidisciplinary research programme for rare 
diseases.  
 
Research in the field of rare diseases is needed to improve the quality of patients' lives. The 
results may also be exploited in the care of patients with less rare diseases. A stronger national 
foundation for research in rare diseases is needed to enable Finland to take part in European 
research projects on rare diseases. Adequate funding must also be reserved for research in 
conditions that are part of the Finnish disease heritage and the related care, as little research in 
this field is conducted anywhere else. 
University level health research is carried out in health care units with national research 
funding. The priorities and objectives of this research are defined by the Ministry of Social 
Affairs and Health for a four-year period at a time. The Ministry grants research funding to the 
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scientific committees of the special catchment areas, which make decisions on allocating 
funding to research projects in their areas on the basis of applications. Research in rare 
diseases and the Finnish disease heritage implemented in cooperation between the catchment 
areas is proposed as one priority area of research. 
Through its research programmes, the Academy of Finland channels funding to areas of 
research that are vital for science and society. The research programmes aim to develop 
selected fields, improve the scientific standard in these fields and create expertise of a new 
type. The programmes stress a multidisciplinary and interdisciplinary approach and 
international cooperation. An initiative will be submitted to the Academy of Finland to 
propose the establishment of a research programme for rare diseases. This research 
programme should include research in disease mechanisms, diagnostics, care and social 
support as well as in the coping and quality of life of people with a rare disease. Information 
about on-going research projects in the field of rare diseases will be collected in a single 
database. 
 
Objectives: 
 Increasing funding allocated to research in rare diseases. 
 Developing a cooperation network on rare diseases and a database of on-going 
research. 
 Promotion of research related to people with a rare disease as users of social and 
health care services and research on the effectiveness of the service system, which 
will be implemented in broad-based cooperation with experts in the sector, 
including patient and client organisations. 
 
Indicators: Share of national research funding earmarked for rare diseases and the Finnish 
disease heritage; Initiative concerning a research programme for rare diseases submitted to 
and a decision to prepare this programme made in the Academy of Finland; Data gathered on 
on-going research. 
 
Responsible actor: Ministry of Social Affairs and Health: Rare diseases as a priority in 
national research funding; University hospitals: Coordination of the research programme 
initiative; National coordinating centre for rare diseases: Compilation of a research database 
 
Timeline: Drafting of national research funding in 2014−2015, implementation at the 
beginning of the forthcoming four-year period in 2016−2019; Initiative concerning the 
research programme submitted to the Academy of Finland in 2014; Research database in 2015 
 
Prerequisites: Confirming the actors responsible for submitting the initiatives 
 
 3.2.2 Action 4: Building up international research cooperation 
 
Possibilities for international research cooperation will be improved by applying for 
membership in the E-RARE project. 
 
As the numbers of patients affected by each individual rare disease are not adequate in Finland 
for clinical studies needed to develop treatments, international networking in the collection of 
information and samples is required. An administrative recommendation on collecting 
registries of this type is needed in Finland to speed up the permit process and enable 
cooperation.  
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Boosting national research funding dedicated to rare diseases will enable Finnish scientists 
to compete for European Union funding sources. Finnish scientists should tap ERC funding 
(European Research Council) and the Horizon 2020 funding programme as sources of funding 
for research projects on rare diseases. 
In 2011, the European Commission and US National Institutes for Health Research 
launched cooperation under the auspices of IRDiRC (International Rare Diseases Research 
Consortium) to promote international cooperation in research in the field of rare diseases. The 
objective of this consortium is to develop 200 new treatments for rare diseases and to find a 
diagnosis for nearly all people with a rare disease by 2020. Each country or organisation 
participating in the IRDiRC is obliged to fund research in the field of rare diseases by USD 10 
million over a five-year period. This funding will be spent on research projects carried out in 
the member country or organisation. The Academy of Finland joined the IRDiRC in June 
2013. 
The European Union's E-RARE-1 project succeeded in uniting European research in rare 
diseases. The E-RARE-2 project that continues until 2014 represents a step further in this 
cooperation. The steering group proposes that the Academy of Finland take part in the next 
phase of E-RARE. 
 
Objectives: 
 Engaging in international cooperation in order to obtain sufficiently large patient 
data sets and to improve the lives of people with a rare disease. 
 Allocating adequate national funding to research in rare diseases that would allow 
participation in the international cooperation project through E-RARE 
membership. 
 
Indicators: Adequate national funding enabling Finland to join E-RARE 
 
Responsible actor: Ministry of Social Affairs and Health, Ministry of Education and Culture, 
Academy of Finland 
 
Timeline: Application for E-RARE membership at the launch of the next phase in 2014 
 
Prerequisites: Adequate national funding 
 
 
 3.3 AREA 3: BETTER AND MORE EFFECTIVE HEALTH 
 CARE FOR PEOPLE LIVING WITH A RARE DISEASE 
 
People living with a rare disease and their families encounter many types of problems in the 
health care system. As the disease is rare, finding a correct diagnosis is often delayed. 
Consequently, a significant share of the patients are assessed by several physicians before a 
correct diagnosis can be pinned down. Some patients are initially given one or more incorrect 
diagnoses, as physicians are not always alert to the possibility of the symptoms being caused 
by a rare disease. In particular, physicians and care personnel working in primary health care 
do not have enough knowledge about rare diseases. In most cases, a precondition for a timely 
diagnosis of a rare disease is simultaneous consultation with several specialist fields, which 
our current health care system does not facilitate. While all tasks requiring special expertise 
require more time than routine work, this time has not been set aside. Delays in finding a 
diagnosis often result in significant harm to people with a rare disease and their families. A 
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more prompt diagnosis would also save society's resources by eliminating the need for being 
assessed by several experts and allowing the timely initiation of care and habilitation.  
Once people with a rare disease have received a correct diagnosis, they meet new 
challenges. While new symptoms and diagnostic changes may occur after the disease has been 
diagnosed, they are not always examined. Many rare diseases require a high level of specialist 
competence and multidisciplinary care. When the care and habilitation of a person with a rare 
disease is being planned, a single actor to assume overall responsibility may be lacking. While 
each field of specialisation concentrates on treating certain symptoms, responsibility for the 
care of the patient as a whole is not necessarily assigned to anyone. As a paediatric patient 
grows up and the responsibility for his or her care shifts to specialised medical care for adults, 
the continuity of care is not always guaranteed. There also are regional differences in access to 
care, and a person with a rare disease is not always referred to a facility with adequate 
competence.  
All health care professionals, for example those in emergency care, do not have enough 
knowledge about rare diseases and the care procedures indicated by them. Specialised medical 
care fails to prepare sufficiently detailed instructions for primary health care. In acute 
situations, patients need rapid access to a unit with skilled staff and adequate experience. 
No pharmacotherapy is currently available for the majority of rare diseases. Specific drugs 
have been developed to treat many rare diseases in recent years, but their effectiveness has 
often not been established with certainty, as small numbers of patients dispersed in different 
countries are not sufficient to reliably confirm the results. Many orphan drugs are also 
expensive, as an orphan drug status granted by the European Commission guarantees drug 
market exclusivity for 10 years, and due to the low demand, pharmaceutical companies have 
no interest in bringing generic products to the market after the period of exclusivity has ended. 
However, pharmaceutical companies are becoming more interested in developing orphan 
drugs and converting drugs intended for the treatment of ordinary illnesses into orphan drugs. 
For optimal outcomes, surgical treatment of rare diseases requires technical skills which 
develop with sufficient repetition of the procedure. Centralisation of rare surgical procedures 
is thus justified. 
Some rare diseases can be diagnosed at birth before the onset of observable symptoms. 
Starting treatment before the onset of symptoms is less expensive and, most importantly, the 
outcome is much better. These diseases can be detected by screening tests carried out on 
newborns, of which only the test for congenital thyroid insufficiency is used in Finland. The 
newborn screening programme should be expanded, following the example of many other 
European countries. A precondition for expanding the screening programme is appropriate 
resource allocation. A working group on screening appointed by the Ministry of Social Affairs 
and Health has considered the necessity of establishing a national screening centre.  
 
 
 3.3.1 Action 5: Clarification of the care pathway for people 
 with a rare disease 
 
The diagnosis and care pathway for people with a rare disease will be streamlined. Awareness 
of the pathways will be spread at various levels of the health care system. A care passport 
should be provided for all people with a rare disease who need one. 
 
In order to find better solutions to problems encountered by people with a rare disease, clear 
care pathways should be created for them, and all levels of health care, NGOs, social services, 
the Social Insurance Institution, people living with a rare disease and their families should be 
informed of them. Figure 1 depicts the care pathway of a person with a rare disease. The 
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pathway includes both the current health care actors and the new centres of expertise and units 
for rare diseases to be set up. For a more detailed description of these, see Actions 6 and 7.  
The point of departure is a patient with symptoms whose disease is so rare that a diagnosis 
cannot be found immediately. His or her care pathway will typically start with primary health 
care or specialised medical care at the primary care level. From this point on, the diagnostics, 
care and habilitation may take any course on the care pathway that optimally responds to the 
patient's situation. The purpose of defining the care pathway is clarifying and accelerating 
diagnostics and care delivery to people with a rare disease, not making the patients' life more 
difficult by centralising care to a small number of units. Each person with a rare disease must 
be able to proceed on their personal care pathway without delay from their initial situation to 
any level required to find a diagnosis and deliver care. The patient must be promptly referred 
further on the care pathway if a correct diagnosis or a suitable form of care cannot be found in 
its initial phases. The main principle is, however, striving to provide care and monitoring close 
to where the patient lives. 
 
     
 
Figure 1.  The care pathway of a person with a rare disease from the search for a diagnosis to 
care delivery and follow-up. In order to find a diagnosis, the pathway must lead to higher 
levels as soon as possible, and in care delivery it must promptly lead back down and close to 
the patient's place of residence. 
 
Some diseases can be diagnosed in a certain unit of specialised medical care. Where the 
disease is so rare that its diagnostics or care are fraught with uncertainties or require 
multidisciplinary competence, the patient must have access to a unit for rare diseases in the 
university hospital of his or her catchment area and a diagnostic examination by a 
multidisciplinary team. This unit will also assume overall responsibility for planning the 
patient's care and the continuity of care when a patient transitions from paediatric to adult 
services, if he or she is not referred to a centre of expertise. Centres of expertise are national 
clusters with expertise in certain groups of diseases. A patient must have access to them if 
necessary. The centre of expertise may direct a patient's care and monitoring that is delivered 
by a unit for rare diseases, another clinic, primary health care or the third sector.  
All levels of health care will engage in close cooperation with social and habilitation 
services to holistically address the situation of people living with a rare disease. An 
assessment of the patient's needs for social services, habilitation and psychosocial support 
should be initiated as soon as possible when the diagnosis has been found.  
21 
 
 
 
The centres of expertise will be part of international networks, and they will be able to 
draw on the expertise and resources of those networks in the diagnostics and care of a patient. 
Other health care units may also collaborate with international experts. In diagnostics and care 
delivery, the primary form of cooperation with international networks of centres of expertise is 
consultation but, if necessary, patients may also be referred to a European centre of expertise 
for assessment. 
The so-called Cross-border Healthcare Directive applies to patients' rights in cross-border 
healthcare (2011/24/EU). The provisions of this Directive have been applied in Finland since 
the beginning of 2014. Under this Directive, a patient is entitled to reimbursement for the costs 
of care received in another member state on the same grounds as for similar care in the 
patient's home country. However, the patient will only receive reimbursement for care that 
would be reimbursed in the patient's home country. In addition, a National Contact Point for 
cross-border healthcare, which provides information on seeking care in other countries by 
Finnish residents and by foreign residents in Finland, operates in connection with the Social 
Insurance Institute. An effort should be made to gradually accumulate expertise in rare 
diseases at the National Contact Point. The Cross-border Healthcare Directive requires 
Finland to specify the selection of services offered by the Finnish health care system to 
establish which costs of care incurred abroad by a patient will be reimbursed in Finland. A 
new government body will be established under the auspices of the Ministry of Social Affairs 
and Health in spring 2014 that will be responsible for defining and continuously updating the 
service selection of the Finnish health care system. While this entity could issue general 
guidance for applying the service selection, it would not comment on decisions concerning the 
care of an individual patient. From the perspective of rare diseases, it should be ensured that 
the service selection includes new treatments of proven effectiveness which are not available 
in Finland but which are offered in another EU Member State. The government body to be set 
up to specify the service selection will consist of a council, a permanent secretariat and a 
network of experts. The participation of centres of expertise for rare diseases or 
representatives of centre of expertise networks must be ensured so that the views of the centres 
of expertise, for example on the development of treatments, would be taken into consideration.  
An effort will be made to ensure that all actors are clear about the care pathway for people 
with a rare disease. The parties that are best placed to diagnose a patient's disease, plan and 
provide care and habilitation, and offer other support will work together. Cooperation may 
take the form of consultations or referrals. The patients or their data may be sent to any unit 
for care delivery or consultation, striving to deliver care and carry out monitoring as close to 
the patient's living area as possible.  
The party responsible for the patient's care will make sure that a care passport in Finnish or 
Swedish is issued to a person with a rare disease if necessary. This passport will facilitate 
transfers from one care facility to another and be helpful in acute situations. The care passport 
will be developed as part of the existing electronic information system, or one to be 
developed. If necessary, the electronic care passport may be printed out and carried by the 
patient. 
 
Objectives:  
 The care pathway of people with a rare disease will be clarified. 
 Each level of the health care system will be familiar with the organisation of 
diagnostics and care delivery for people with a rare disease. 
 If necessary, people with a rare disease will have care passports in Finnish or 
Swedish. 
 
Indicators: Health care professionals have been informed of the care pathway for people with 
a rare disease; a care passport in the electronic system 
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Responsible actor: Catchment areas: agreements on care pathways for people with a rare 
disease; National Institute for Health and Welfare: Care passport 
 
Timeline: During the plan period 
 
Prerequisites: Establishment of the units and centres of expertise for rare diseases, 
identification of a suitable electronic system for care passports 
 
 3.3.2 Action 6: Units for rare diseases in university hospitals 
 
A unit for rare diseases will be set up in each university hospital. Each unit will have a 
coordinator and a multidisciplinary team. 
 
People with a rare disease need an actor who will assume overall responsibility for their care. 
This means that patients will receive better care faster, and resources will also be saved. While 
plenty of resources are currently spent on the diagnostics and care of people with a rare 
disease, a diagnosis and an optimal care pathway are not necessarily found. A correct care 
pathway would save resources and speed up the initiation of appropriate care. Adults with a 
rare disease in particular often lack a party responsible for their care. Specialists in different 
fields rarely have an opportunity to get together and consider the diagnosis of patients 
requiring multidisciplinary competence and their care as a whole.  
Units for rare diseases need to be established in university hospitals where some of the 
existing functions will be reorganised to achieve better outcomes. Six per cent of the 
population will be affected by a rare disease during their lifetime. The share of people with a 
rare disease is significantly higher in specialised medical care, and they account for a large 
group among the patients of university hospitals. The unit for rare diseases will facilitate 
multidisciplinary meetings to assess patients whose diagnosis is difficult to pin down and to 
coordinate their care. The units will assume responsibility for those paediatric and adult 
patients in their catchment areas who display symptoms consistent with a rare disease but for 
whom no diagnosis has been found in primary health care or in a specialised medical care unit. 
The units will also be responsible for people diagnosed with a rare disease who require 
multidisciplinary competence and for whom a dedicated centre of excellence cannot be set up 
in Finland, or who cannot be cared for elsewhere in specialised medical care units. The 
activities of the unit for rare diseases should cover all age groups. 
Each unit for rare diseases will need a coordinator who is a designated person working in 
the university hospital. He or she will liaise with primary health care and serve as an 
information channel between various specialisations and social services. The coordinator will 
organise the multidisciplinary meetings to discuss rare diseases. A multidisciplinary team will 
operate in the unit for rare diseases. It will deal with undiagnosed patients whose symptoms 
are consistent with a rare disease. A selection of specialists will be invited to take part in the 
team as seen necessary in the case of each patient. The units should have expertise in medical 
genetics. The unit for rare diseases will develop flexible cooperation between various clinics 
and coordinate the transition of children to adult services if necessary, and the transition of 
patients to primary health care and social services. 
The unit for rare diseases will work together with other similar units, centres of expertise, 
international networks and patient organisations. In addition to diagnostics and care, the unit 
will coordinate the habilitation and support measures related to rare diseases for which a 
suitable coordinating party cannot be found in the centres of expertise or in any specialist 
field. 
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If a rare disease is suspected in a patient, the threshold for consulting a unit for rare 
diseases or a centre of expertise should be low. Such patients are primarily diagnosed and 
cared for in primary health care or in a specialised medical care clinic. If necessary, however, 
patients in need of a diagnosis or appropriate care will be referred to a unit for rare diseases or 
a national centre of expertise without delay.  
The special catchment areas will assess the cooperation between the university hospital, 
central hospital and primary health care. The unit for rare diseases will mainly be responsible 
for the coordination of care; patients may receive care in a clinic of a university hospital, in a 
central hospital or in primary health care services close to their homes, unless specialised 
medical care is needed. The team on rare diseases will periodically organise meetings to which 
parties involved in providing care for people with a rare disease will be invited from primary 
health care, specialised fields or units providing habilitation. The unit will promote the 
availability of information on rare diseases in the social welfare and health care system. 
Information will also be available on the website of the unit for rare diseases which will list 
the contact information of experts. 
As far as possible, the unit for rare diseases will be structured as a sustainable part of the 
university hospital, ensuring that the arrangement works well for the hospital. For example, 
the unit may operate in connection with a medical genetics clinic, which also plays an 
important role in the diagnostics of rare diseases in other respects. Additional funding is 
needed for the unit for rare diseases, allowing the establishment of the posts of a coordinator 
and a coordinating nurse as well as the organisation of sufficiently frequent multidisciplinary 
meetings. The hospital management must ensure that the multidisciplinary team members 
have the possibility of taking part in meetings to discuss rare diseases. 
 
Objectives: 
 The unit for rare diseases will be responsible for the diagnostics and coordination 
of care in case of those patients for whom no clear specialised field exists. 
 Cooperation between university hospitals will be facilitated. 
 Transitions from paediatric clinics to adult services and primary health care will 
be smooth. 
 The possibility to follow a multidisciplinary approach to diagnosis and care of rare 
diseases will be secured in the health care services, even if such an approach is 
often time-consuming.  
 The availability of information on rare diseases in the social welfare and health 
care system will be promoted.  
 
Indicators: Units for rare diseases established (5); Coordinators and coordinating nurses for 
rare diseases appointed (5 + 5) 
 
Responsible actor: Helsinki University Central Hospital, Turku University Central Hospital, 
Tampere University Central Hospital, Oulu University Hospital, Kuopio University Hospital 
 
Timeline: Planning of units for rare diseases in 2014, appointment of coordinators and 
coordinating nurses and unit establishment in 2015, regular operation of teams and online 
information activities in 2016 
 
Prerequisites: Finding the resources to form units for rare diseases in university hospitals 
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 3.3.3 Action 7: Centres of expertise for rare diseases 
 
Centres of expertise for rare diseases meeting EU criteria and national centres of expertise 
will be established in Finland. 
 
As the number of people affected by any single rare disease is low, it would be useful to 
compile information on their management. This would prevent the fragmentation of resources 
and competence, and each person with a rare disease would have access to the best possible 
care. The steering group proposes that national centres of expertise focusing on certain groups 
of rare diseases be established in Finland. The centres of expertise would bring cost savings by 
reducing unnecessary visits to doctors, periods of in-patient care and costs of malpractice, and 
by making patient guidance and care more efficient. They can be centres of expertise focusing 
on particular groups of diseases that meet EU criteria and are part of international cooperation 
networks, or national centres for diseases or groups of diseases with the primarily task of 
facilitating the sharing of expertise at the national level rather than meeting EU criteria. These 
centres of expertise will be designated as EU level or national centres of expertise. 
Some centres of expertise already are up and running in Finland: university hospitals have  
special competence related to certain diseases, which other hospitals draw upon by consulting 
the specialists. Hover, clear cooperation and the possibility of focusing on a certain disease or 
group of diseases have so far been lacking. The centres of expertise may be formed in 
cooperation between various units of university hospitals or third-sector actors. The centres of 
expertise will be set up sustainably as part of the health care system structures. This way, they 
will depend on structural arrangements for their continuity rather than on individual 
specialists.  
As the centre of expertise must have a specified, systematic and continuous position in the 
Finnish health care system, third-sector actors cannot usually form independent centres of 
expertise; they may, however, form centres of expertise in cooperation with hospitals. One 
centre of expertise will be set up for each disease or group of diseases. When a rare disease is 
suspected, the centre of expertise will be contacted either in the diagnostic phase or 
subsequently. The centre of expertise will direct the diagnostics, care, habilitation and 
monitoring related to the disease, but once the patient's care has been planned, responsibility 
for it will revert to a dedicated health care professional in the patient's own hospital district, 
who will liaise with the centre of expertise. Units for rare diseases in university hospitals will 
work closely together with the centres of expertise. The centres of expertise may also take 
their expertise to the patients: the experts may travel to different hospitals, rather than the 
patients travelling to the centres. 
The network consisting of centres of expertise, units for rare diseases, various 
specialisations and primary health care will work together to ensure that competence is 
transferred to the party responsible for the patient's care. The centres of expertise will offer 
training to all professional groups of the health care system. The main principle of delivering 
care to people with a rare disease should be that patients have access to diagnoses and care 
regardless of where they live, information is shared effectively, and various hospitals draw on 
the competence of the centres of expertise. A database of the centres of expertise will be put 
together where social welfare and health care professionals and people with a rare disease can 
easily find information about expertise available in Finland in each rare disease. 
 Cooperation between centres of expertise and patient organisations will be vital, and 
determined efforts will be made to develop it. The centres of expertise will engage in regular 
cooperation with patient organisations whose expertise will also be utilised in the planning 
phase of the centres. The centre of expertise will put together a client panel in cooperation 
with patient organisations. The panel will comment on the general policies of the centre of 
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expertise and, if necessary, it may bring up issues on its own initiative. Patient organisations 
will also take part in periodic evaluations of the centres of expertise, and they will be actively 
engaged in the development of social support.  
The centres of expertise currently have no legal status, and the work must thus start with an 
assessment of the need to amend legislation. EU level centres of expertise must meet the 
European Commission's criteria which are to be laid down in spring 2014. These centres of 
expertise must be part of the European networks of centres of expertise which play a key role 
in promoting diagnosis and care as expertise and patients move across the borders. The centres 
of expertise will not only comprise physicians and nurses, but also professionals of other 
fields, including physiotherapists and social workers. The centres will have competence in 
diagnostics, care, habilitation and social services. 
A formal negotiation mechanism will be put in place between the special catchment areas 
and the Ministry of Social Affairs and Health to designate centres of expertise. The process of 
designating both national and EU level centres of expertise will begin with joint negotiations 
between the special catchment areas. The Ministry of Social Affairs and Health will inform 
hospital districts and non-governmental organizations that provide health services to people 
with a rare disease about the launch of the designation process and request proposals for 
centres of expertise. When a call for applications is launched, no groups of diseases will be 
named, as in the initial phase the aim will be to form centres around existing expertise. In 
order to register as applicants, candidates must have engaged in negotiations with fields of 
specialisation in the special catchment areas, ensuring that the establishment of the centre of 
expertise has broader support. When applying for the status of a EU level centre of expertise, a 
unit must also describe how it intends to meet the European Commission's criteria. The 
establishment of a centre of expertise may be proposed by the management of a university 
hospital, senior physicians in fields of specialisation, experts in rare diseases or third-sector 
actors as a result of a negotiation process. Each centre must cover a clear-cut group of rare 
diseases or, in the case of a national centre, a single rare disease. At a later stage, centres of 
expertise may also be established by way of invitation: if needs for a centre of expertise for a 
certain group of diseases emerges, the Ministry of Social Affairs and Health may declare an 
application round for the centre in question open and launch negotiations with units that could 
serve in this role.  
Centres of expertise will be designated for a term that is long enough to allow for long-term 
financial planning and enable the centre to develop. This time period will be specified in 
compliance with the forthcoming EU legal act. When centres of expertise are designated based 
on application, representatives of specialist fields in all hospital districts and the relevant 
patient organisation will be consulted. The designation of centres of expertise will be drafted 
by the national coordinating centre for rare diseases. The university hospitals and patient 
organisations will be represented in the national centre's board. The centres of expertise will 
be designated by the Ministry of Social Affairs and Health. 
 
Objectives: 
 Examining any legislative amendments required to establish centres of expertise.  
 Initiating the establishment of centres of expertise for rare diseases during the plan 
period in Finland. 
 Some of the centres will have strategies for meeting the EU criteria. 
 All levels of health care have been informed about the centres of excellence for 
rare diseases. The centres of expertise are sharing their expertise with all levels of 
the social welfare and health care system. 
 
Indicators: Centres of expertise for rare diseases have been established; Database on the 
centres of expertise has been created; Number of referrals to centres of expertise 
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Responsible actor: Ministry of Social Affairs and Health, hospital districts and university 
hospitals 
 
Timeline: Examination of the need for legislative amendments in 2014, more detailed 
planning and drafting of centres of expertise in 2014, round of applications and negotiations in 
2015 
 
Prerequisites: Putting the required legislation in place, financial resources for establishing the 
centres of expertise  
 
 
3.3.4 Action 8: Providing more education and training 
 
Social welfare and health care professionals will be provided with more education and 
training in the field of rare diseases. 
 
According to a study (2009) conducted by EURORDIS, the European umbrella organisation 
for patients with a rare disease, taking the possibility of a rare disease into consideration 
speeds up the correct diagnosis of a rare disease. A key method for spreading awareness 
among physicians who diagnose rare diseases and other health care personnel is providing 
them with more education and training in the field of rare diseases. This education and 
training should be offered as part of both initial and continuing education. 
In basic medical training, content related to rare diseases could be partly integrated in 
medical genetics studies, and many educational institutions already do so. Due to a lack of 
personnel resources, a comprehensive course in medical genetics is not included in the syllabi 
of medical faculties in all universities.  
The steering group proposes that a concept focusing on rare diseases be added to the 
education programme of medical students and students of other social welfare and health care 
fields. This concept would direct the students in finding out what types of rare diseases there 
are, how to suspect a rare disease rather than a more common one, how to deal with a rare 
disease, where the patients can be directed and how significant thinking of the possibility of a 
rare disease is in terms of a prompt diagnosis. To make sure that professionals can encounter 
people with a rare disease holistically and as indicated by the patient's situation, teaching 
about the multi-channel habilitation system will be included in health care and social welfare 
qualifications in all fields.  
Continuing education related to rare diseases should be organised for all fields of social 
welfare and health care. The units and centres of expertise for rare diseases will provide 
training for different levels of the health care system and for professionals of habilitation and 
social services. The Finnish Society of Medical Genetics has already decided to put together a 
training package intended for professionals working in primary health care and specialised 
medical care. 
The existing service user trainer networks should be exploited more extensively in 
education. In Eastern Finland, service user training has already been fully integrated in the 
education, allowing students to benefit from first-hand knowledge about rare diseases as part 
of their theoretical studies. The service user trainers receive careful coaching, and the only 
costs incurred by the educational institution are the trainer's travel costs. 
 
Objectives: 
 Knowledge of rare diseases among social welfare and health care sector 
professionals will be built up. 
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 Health care, social welfare and habilitation professionals who deal with rare 
diseases will have up-to-date information about rare diseases. 
 
Indicators: Emphasis on rare diseases in the education and training of students in the social 
welfare and health care sector; Training events related to rare diseases organised for social 
welfare and health care personnel 
 
Responsible actor: Ministry of Education and Culture, universities and polytechnics: Emphasis 
on rare diseases in the education and training of students in the social welfare and health care 
sector; Units and centres of expertise for rare diseases: Training courses intended for social 
welfare and health care professionals 
 
Timeline: Preparing a study concept focusing on rare diseases to be included in qualifications 
in the social welfare and health care sector in 2014−2015; annual training events from 2014 
 
Prerequisites: Universities' and polytechnics' approval for modifying education programmes 
 
 3.3.5 Action 9: Promoting the availability of orphan drugs 
 
The availability and reimbursement of drugs and medicinal products used to treat rare 
diseases will be promoted. 
 
As the patient numbers are low and the development of new drugs is expensive, the 
pharmaceutical industry is unwilling to invest in the research and development of orphan 
drugs. Dedicated support measures are thus needed. Due to the small markets, 
pharmacotherapy used to treat rare diseases usually is more expensive than that of more 
common diseases. People with a rare disease experience long-term and often lifelong needs 
for medication. As people with a rare disease are entitled to the same quality of care as other 
patients, the authorities in various countries have developed incentives for the biotechnology 
and pharmaceutical industry in order to support the research, development and marketing of 
orphan drugs. 
The Regulation on orphan medicinal products adopted in 1999 lays down the EU policy on 
orphan drugs in the Member States. Under this regulation, a medicinal product shall be 
designated as an orphan medicinal product if it is intended for a condition affecting not more 
than five in 10 thousand persons in the Community. The condition must be life-threatening or 
chronically debilitating. If the condition is less severe than this, a product may be designated 
as an orphan medicinal product if it is unlikely that the marketing of the medicinal product in 
the Community would generate sufficient return to justify the necessary investment. Another 
condition is that there exists no other method of treatment of the condition in question or that 
the product will be of significant benefit to those affected by that condition.  
Finland is committed to the incentive system for developing orphan drugs. The European 
Commission may grant an exclusive marketing authorisation for an orphan drug for ten years. 
During this time, generic drugs will not be granted a marketing authorisation unless they are 
significantly more effective. While the marketing authorisation is granted at the European 
level, eligibility for reimbursement must be applied for separately in each country. In Finland, 
a drug must be eligible for basic reimbursement before special reimbursement can be paid. Its 
therapeutic value, necessity and cost-effectiveness in use must be proven. Eligibility for 
special reimbursement may be granted for medicinal products that are used to treat severe and 
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long-term illnesses listed in a Government Decree. Another criterion for eligibility for special 
reimbursement of a medicinal product is that the wholesale price proposed for it is reasonable. 
When decisions on eligibility for special reimbursement are being made, the funds available 
for special reimbursements will be taken into account.  
The availability of orphan drugs is reasonably good in Finland, and their continued 
availability should be safeguarded. The EU Directive on patients' rights in cross-border 
healthcare includes mutual recognition of prescriptions; in other words, holders of a European 
prescription issued in Finland can purchase drugs in other European countries. Prescriptions 
written in another EU Member State will be filled if the drug has a marketing authorisation in 
the Member State where it is to be purchased. 
Almost all orphan drugs available in Finland that are used in outpatient care are eligible for 
reimbursement. As orphan drugs are expensive, they should also qualify for reimbursement in 
the future. Due to ambiguities in funding responsibilities, in certain situations an individual 
patient may end up paying significant amounts for their drugs. According to a working group 
preparing an overall reform of the drugs reimbursement system, funding responsibilities 
related to orphan drugs and their reimbursement from the health insurance should be examined 
in detail (Final report of the working group on developing the drugs reimbursement system, 
Reports and memorandums of the Ministry of Social Affairs and Health 2012:33). 
One aspect of this problem is drugs intended for the treatment of common illnesses where 
research-based evidence of a high quality indicates that the drugs are effective in the treatment 
of rare diseases but they are not eligible for reimbursement when used to treat a rare disease. 
The extent of this problem and the factors behind it should be studied. The steering group 
proposes that if necessary, the Ministry of Social Affairs and Health should act with initiative 
both in the national and the international context and promote the extension of therapeutic 
indications of drugs in the market to also include those rare diseases in whose treatment the 
drug is effective in the light of scientific evidence. 
If the drug does not have marketing authorisation in Finland, the Finnish Medicines 
Agency may on certain conditions grant a special authorisation to a medicinal product for the 
treatment of an individual patient or a patient group for a maximum period of one year. 
Eligibility for reimbursement for a medicinal product delivered under a special authorisation 
may be applied for by an individual user, a pharmacy on behalf of a patient, a wholesaler, or a 
pharmaceutical company.  Physicians, as well as people with a rare disease and their families, 
need more information and advice about the possibility of applying for a special authorisation 
and eligibility for reimbursement for a medicinal product delivered under a special 
authorisation. 
The availability and reimbursement of costs of not only medicinal products but also 
nutritional products are fraught with problems. A Government decree lists the severe diseases 
where either 35% or 65% of the costs incurred for therapeutically used clinical nutritional 
products are reimbursed to the patients. For example, this decree does not cover severe rare 
epilepsies treated with nutritional products. An effort should thus be made to include in the 
decree all severe illnesses where research-based evidence exists to support treatment with 
clinical nutritional products. Patients with severe nutrient malabsorption only qualify for the 
lower rate of reimbursement at 35%. The steering group proposes that nutritional products 
used to treat these conditions be made eligible for reimbursement based on the higher rate. 
While nutritional and similar products are a lifeline for some people with a rare disease, not all 
products are yet covered by the reimbursement scheme. 
 
Objectives: 
 Ensuring the availability of orphan drugs. 
 Carrying out a survey of drugs used to treat rare diseases. 
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 If necessary, promoting the extension of therapeutic indications of drugs already 
on the market to rare diseases for which there is scientific evidence of a drug's 
therapeutic effectiveness. 
 Including all severe illnesses where there is scientific evidence supporting 
treatment with clinical nutritional products in the decree on the eligibility for 
reimbursement of nutritional products.  
 Reimbursing 65% of the costs incurred for clinical nutritional products used to 
treat severe malabsorption. 
 Spreading awareness of the possibility of applying for eligibility for 
reimbursement in case of medicinal products supplied under a special 
authorisation. 
 
Indicators: The number and share of orphan drugs eligible for reimbursement in all orphan 
drugs used in outpatient care; Awareness of the possibility of applying for eligibility for 
reimbursement in case of a medicinal product supplied under a special authorisation (patient 
survey) 
 
Responsible actor: Ministry of Social Affairs and Health: Amendments to the Health 
Insurance Act, spreading information about the application procedure for eligibility for 
reimbursement in case of medicinal products supplied under a special authorisation; Social 
Insurance Institution: A survey of drugs used to treat rare diseases 
 
Timeline: Legislative amendments in force in 2017 
 
Prerequisites: Amendments in legislation on drugs reimbursement 
 
 
 3.4 AREA 4: COORDINATION OF EXPERTISE AND 
 KNOWLEDGE SHARING  
 
One of the key problems associated with rare diseases is the sporadic nature of knowledge and 
expertise. Health care professionals and people with a rare disease, to say nothing about social 
welfare actors, cannot access the knowledge and expertise that is available, as it has not been 
collected in one location. There also are gaps in knowledge about rare diseases in many areas, 
which delays diagnosis and access to appropriate care. 
An actor to assume responsibility for coordinating rare diseases issues is lacking in Finland. 
In addition to collecting and spreading information, an actor of this nature would be needed to 
administrate the dedicated measures required by rare diseases and to monitor their 
implementation, to create links between competence in rare diseases at different levels of the 
health care system, to serve as a forum for dialogue between various stakeholders and to 
maintain international cooperation networks. 
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 3.4.1 Action 10: A national coordinating centre for rare 
 diseases 
 
A national coordinating centre for rare diseases will be set up. 
 
A national coordinating centre for rare diseases will be set up in Finland to serve as an 
administrative link between primary health care, different fields of specialised medical care, 
units for rare diseases, centres of expertise, third-sector actors, the Social Insurance Institution, 
social services, and other EU programmes and centres for rare diseases. It would be 
appropriate to establish this centre under the auspices of the National Institute for Health and 
Welfare. Its board should include representatives of the health care and social welfare systems, 
centres of expertise, the Social Insurance Institution, the third sector and patient organisations. 
The centre will convene a national forum on rare diseases that will meet as necessary but at 
least once a year and comment on topical issues in the field of rare diseases. The national 
centre's work would be based on the forum's opinions. The national forum should bring 
together all stakeholders in the field of rare diseases across a very broad spectrum. The centre 
will need a coordinator and an expert. 
The centre's key task will be developing the service system to meet the needs of people 
with a rare disease as effectively as possible and as set out in the National Plan for Rare 
Diseases. The national centre will see to the division of responsibilities for the implementation 
of National Plan actions and be in charge of the progress, monitoring and evaluation of the 
actions and the setting of new objectives. The national coordinating centre for rare diseases 
will be responsible for drafting the designation of centres of expertise: it will coordinate the 
process aiming to establish centres of expertise and make proposals for the designation of 
centres to the Ministry of Social Affairs and Health. 
Other tasks of the national centre will include developing independent and extensive 
education and training, coordinating the preparation of clinical care recommendations for rare 
diseases, and coordinating expertise and knowledge in cooperation with centres of expertise, 
units for rare diseases and NGOs. It will also coordinate international research cooperation. 
The national coordinating centre for rare diseases will be a member of European cooperation 
organs and pass on information about international expert forums. 
As the National Institute for Health and Welfare will be faced with significant cuts in its 
resources, setting up the centre within the Institute is not possible at this stage, and its 
establishment has to be postponed to a later date. The steering group recommends that a 
smaller informal group be set up to implement the programme that would meet a few times in 
2014. This group should contain representatives from the Ministry of Social Affairs and 
Health, the National Institute for Health and Welfare, the Social Insurance Institution, all 
university hospitals, the Association of Finnish Local and Regional Authorities, the Finnish 
Network for Rare Diseases, Orphanet and the HARSO network.  At the end of 2014, the 
possibilities of establishing a more permanent national coordination structure would be 
examined. The steering group further proposes negotiations between university hospitals to 
establish which one of them could assume responsibility for coordinating clinical activities in 
the field of rare diseases on a temporary basis.  
 
Objectives: 
 Information on Finnish expertise in rare diseases will be collected systematically 
and in a coordinated fashion. 
 A national centre will be established that will assume responsibility for good 
governance and planning in the field of rare diseases. 
 A national forum on rare diseases will be set up, and it will meet regularly. 
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Indicators: Decision to establish a national coordinating centre for rare diseases; Recruitment 
of a coordinator and a specialist; Compilation of a database containing information relevant to 
rare diseases  
 
Responsible actor: Ministry of Social Affairs and Health, National Institute for Health and 
Welfare, university hospitals 
 
Timeline: A centre coordinating rare diseases and a national forum set up to coordinate plan 
implementation from 2015 
 
Prerequisites: Financial resources for establishing the centre 
 
 3.4.2 Action 11: Systematic collection and sharing of 
 information 
 
A comprehensive online database of rare diseases in Finnish and Swedish will be created. 
Information will be provided to people with a rare disease, their families and social welfare 
and health care professionals by a dedicated helpline. A yearly seminar on rare diseases will 
be organised in cooperation with patient organisations.  
 
Plenty of information on rare diseases is already available on the Internet, but this information 
is to some extent scattered and there are gaps in it. There also is a number of rare diseases on 
which no information can be found in Finnish or Swedish. The national coordinating centre 
for rare diseases will be responsible for the systematic collection and publication of 
information on the Internet. It will organise the collection of information on units and centres 
of expertise for rare diseases, and from people with a rare disease and patient organisations. 
The national centre will also collect information about care, habilitation and social services in 
cooperation with patient organisations. Patient organisations are often important sources of 
information for people with a rare disease and their families, a fact that should be taken into 
account in the dissemination of information.  
A comprehensive Finnish online database on rare diseases can be created by translating 
into Finnish and Swedish the contents of Orphanet, the existing online service for rare diseases 
and orphan drugs, currently maintained by the Norio Centre. Orphanet is a cooperation project 
in which some forty countries take part. The Orphanet team in each country collects 
information on specialist clinics, medical laboratories, research projects and patient 
organisations in their own country. This information is accessible to everyone free of charge. 
When creating the database, Orphanet should be taken into consideration to avoid overlapping 
work. The national coordinating centre for rare diseases and the Ministry of Social Affairs and 
Health will agree upon database implementation and cooperation with the third sector. The 
database should be regularly updated, and all those working with rare diseases should be 
informed about its existence. 
In addition to an electronic database, general advice on rare diseases and expertise in them 
available in Finland will be needed for both citizens and social welfare and health care actors. 
Currently, this type of service is provided by third-sector actors through helplines and 
electronic query services, which could also be a good operating model in the future. Another 
possibility is that the special catchment areas agree to set up a general helpline at a certain unit 
for rare diseases. 
The national centre will assume responsibility for organising an annual seminar. This 
seminar will be organised in connection with the national forum, and it will discuss topical 
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issues in the field of rare diseases. All parties to whom rare diseases are relevant will be 
invited to the seminar on rare diseases. 
 
Objectives: 
 Information related to rare diseases, including information on research, health care 
and social services and support needed by people with a rare disease, will be 
collected and offered systematically. 
 The activities of the Finnish Orphanet will be accounted for when creating a 
Finnish and Swedish database on rare diseases. 
 Actors in the field of rare diseases will meet every year at an annual seminar. 
 
Indicators: A database in Finnish and Swedish exist; Orphanet continues to be updated; 
Annual seminar on rare diseases; People with a rare disease can find the information they need 
(patient survey) 
 
Responsible actor: National coordinating centre for rare diseases  
 
Timeline: Continuously, starting from the beginning of the plan period in 2014 
 
Prerequisites: No obstacles 
 
 
 3.5 AREA 5: OFFERING HOLISTIC SUPPORT TO AND 
 EMPOWERMENT OF PEOPLE WITH A RARE 
 DISEASE 
 
Once a person with a rare disease has received a correct diagnosis and even earlier if 
necessary, suitable health and social services will be sought for him or her, and habilitation 
will be initiated together with the client and, where necessary, his or her family. The problem 
often lies in the lack of a holistic approach to improving the quality of life of a person with a 
rare disease. People with a rare disease and their families may also encounter many types of 
challenges as users of ordinary services, for example at a maternity clinic or in a day-care 
centre or an educational institution. Instead of an approach based on the diagnosis, the 
evaluation of service needs should address the special needs of the individual patient. The 
objective should be that each person can live a full life of his or her own choosing regardless 
of a rare disease, and receive not only appropriate care and habilitation but also the 
psychosocial support indicated by his or her needs.  
Social services do not always fully meet the needs of people with a rare disease: 
information provided about the available social services may be inadequate, and a large share 
of people with a rare disease and their families are dissatisfied with the quality of social 
services. There also are regional differences in the availability of social support. Information 
about social security and welfare services is fragmented, the authorities may have little or no 
experience of rare diseases, and no big picture exists of the social services' capabilities for 
meeting the needs of people with a rare disease and their families.  Because of these problems, 
research in the effectiveness of services in the field of rare diseases is also needed.   
Increasing the clients' inclusion and participation in their own lives and supporting their 
coping with everyday life are key objectives in the development of social welfare and health 
care legislation and service system. The provision of social services and support start from the 
client's needs, regardless of the underlying diagnosis.    
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The habilitation system is complex and fragmented. Habilitation is organised by the health 
care system, the social services, the education services, the Social Insurance Institution and the 
labour administration, and each actor defines their target groups and objectives differently. 
Rare diseases are often diagnosed already in childhood. During their lives and in various 
phases of their disease, patients may need habilitation offered by several different actors. 
Extensive cooperation is needed in the planning of care and habilitation to ensure timely 
habilitation that would lead into the client's optimal functional capacity and work ability. 
Directing people with a rare disease to timely habilitation services indicated by their needs 
is difficult, and cooperation between the care facility, the Social Insurance Institution and the 
habilitation service provider is not always adequate. Competences in different fields do not 
always meet: health care personnel have inadequate knowledge about and competence in 
habilitation, and information about the Social Insurance Institution's habilitation services is not 
always successfully communicated to the health care services. On the other hand, the health 
care system's knowledge about habilitation needs related to rare diseases and new forms of 
treatment and habilitation do not always reach those in charge of planning the Social 
Insurance Institution's habilitation services on a sufficiently broad front. The Social Insurance 
Institution does not have consistent information about the care facilities, and thus correct 
actors are not always consulted. 
People with a rare disease or their families often are themselves highly knowledgeable 
about their situation, and they know what kind of services the person with a rare disease 
needs. Many patient organisations also have plenty of knowledge about the experiences and 
needs of people with a rare disease. However, they are not always adequately taken into 
consideration in the planning of social and health services. Availability of psychosocial 
support to people with a rare disease and their families and stronger participation of patients 
and families in the planning of care and services would improve the holistic implementation of 
care and support.  
The client and patient organisations offering peer support and other psychosocial support 
receive funding intended for NGOs for the development of these activities from such funding 
providers as Finland’s Slot Machine Association (RAY). 
 
 3.5.1 Action 12: Developing social support and habilitation 
 
More information will be disseminated about social and habilitation services. Centres of 
expertise, units for rare diseases, NGOs, the Social Insurance Institution and municipal social 
services will work together in closer cooperation in order to anticipate the habilitation needs 
of a person with a rare disease, to plan services and to address the need for holistic support of 
the person with a rare disease. People with a rare disease and, if necessary, their families will 
take part in the planning of care, habilitation and social services.  
 
Cooperation during the habilitation period of a person with a rare disease will be taken into 
consideration in the work of units and centres of expertise for rare diseases to ensure that 
physical and psychological habilitation alike optimally support the care and overall objectives 
of the person with a rare disease. For example, this will enable network-based negotiations 
between the rehabilitee, the care facility, the habilitation service provider and social services. 
Liaising with parties providing habilitation services, the Social Insurance Institution, social 
services and NGOs will be made part of the operating model of the centres of expertise when 
planning the care, habilitation and social support of a person with a rare disease. Assessment 
of the possibilities offered by habilitation that the Social Insurance Institution is responsible 
for providing will be included in the operating model of units for rare diseases. In case of 
people with a rare disease requiring multidisciplinary competence and extensive support, the 
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duty of drawing up a care and habilitation plan as indicated by the client's needs and liaising 
with social services will be assigned to a dedicated person.  
Rehabilitation is often demanding, and treatments are advancing constantly. Without 
information exchange, habilitation cannot be provided as indicated by the client's needs, and 
people with a rare disease will not have access to habilitation measures indicated by their 
needs and guidance that enables habilitation. Centres of expertise and units for rare diseases 
will serve as coordinating units for the planning of care and habilitation together with health 
care services, the habilitation team of the Social Insurance Institution and social services. 
Primary health care will also strive to appoint an actor to coordinate habilitation. The actor 
delivering care to a person with a rare disease will inform the municipality and the person 
him/herself about aspects that need to be taken into consideration in the habilitation process.  
Closer cooperation between various parties is vital, so that education and training can be 
targeted at those making decisions about habilitation and social welfare and health care 
personnel working with people affected by a rare disease, and people with a rare disease can 
be directed to suitable habilitation services and appropriate type of assistance. People with a 
rare disease should themselves have the possibility of participating in their care and service 
process and influencing it in all of its phases, as well as being informed about it by the actors 
involved in the process.   
Information about the social security and service system and habilitation should be 
distributed more effectively. The units and centres of expertise for rare diseases should have 
data banks on habilitation and social services where other health care units can find 
information. Information about the social security system and habilitation is provided by 
habilitation advisers and social workers at hospitals and the municipal social services, 
especially services for the disabled. Support for client work in the field of services for the 
disabled and information for clients is available from the electronic Handbook on Disability 
Services, which is part of the National Institute for Health and Welfare's web service. In 2013, 
a separate section on services for children and young people was launched. Rare diseases 
should also be included as a separate section in the handbook. National health and patient 
organisations and organisations for people with disabilities have joined their forces in 
preparing a guide to social security for persons with long-term illnesses and disabilities. This 
guide supports NGO employees who provide advice and guidance to their members. The 
national coordinating centre for rare diseases will collect existing information in a single 
location and share it with all levels of the social welfare and health care system. 
When developing cooperation and information about habilitation and social services in the 
field of rare diseases, interfaces with the on-going projects of the Ministry of Social Affairs 
and Health aiming to reform social and health care service structures, the Social Welfare Act 
and legislation on services for the disabled and to develop informal care and multidisciplinary 
habilitation will be taken into consideration. It has been proposed that under the new Social 
Welfare Act, a dedicated employee could be assigned to those clients who need several social 
services. This operating model would promote the planning of service packages so that the 
individual needs of people with a rare disease could be addressed better. The possible need for 
support of family members assisting a person with a rare illness should also be investigated.  
Peer support offered by patient organisations to people with a rare disease is extremely 
important. However, Finland's Slot Machine Association no longer offers sufficient funding 
for patient organisations. RAY grants to patient organisations should thus be increased to 
provide NGOs with better possibilities of offering peer support. 
 
Objectives: 
 There will be closer and more systematic cooperation between health, social and 
habilitation services so that the needs of a person with a rare disease can be 
addressed holistically. 
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 People with a rare disease and, if necessary, their families will take part in the 
planning of service packages, and they will be able to exert influence in the way 
the services are arranged. 
 A service plan will be drawn up for people with a rare disease requiring 
multidisciplinary competence. 
 Information about timely habilitation and social services will be easily available, 
and it will be distributed to social welfare and health care professionals and people 
with a rare disease. 
 New information about rare diseases will be disseminated to the Social Insurance 
Institution, patient organisations, insurance companies and social and health 
service organisers and providers. 
 Patient organisations' possibilities of organising peer activities will be supported. 
 
Indicators: Liaising between health, social and habilitation services when planning the care 
and habilitation of people with a rare disease (reports from centres of expertise); Service plans 
drawn up (patient survey); Data bank of social and habilitation services compiled; Trends in 
RAY grants to patient organisations  
 
Responsible actor: The national coordinating centre for rare diseases, units for rare diseases, 
centres of expertise, the Social Insurance Institution, municipal social services; the National 
Institute for Health and Welfare: A section on rare diseases in the Handbook on Disability 
Services    
 
Timeline: After the establishment of the national centre, units for rare diseases and centres of 
expertise from 2016 on 
 
Prerequisites: Appointment of a coordinating party; cooperation to complement the Handbook 
on Disability Services 
 
 3.5.2 Action 13: Empowerment of people with a rare disease 
 
People with a rare disease, their families and patient organisations will have better 
opportunities to participate in decision making and in the planning of services in the field of 
rare diseases. 
 
In the European Commission Recommendation (2009), it is stated that patients and patient 
organisations should be consulted on policies in the field of rare diseases. According to the 
quality criteria for centres of expertise formulated by EUCERD (European Union Committee 
of Experts on Rare Diseases), the centres of expertise collaborate with patient organisations to 
bring in the patients’ perspective (Appendix 2). The empowerment of patients and their 
families and their participation in planning services should be promoted, and patient 
organisations' possibilities of exerting influence should be improved at various levels. This 
should also be the point of departure for developing the social welfare and health care 
legislation and service system. 
Individual persons with a rare disease and their family members should be provided with 
adequate information about care, habilitation and social and support services. This role of low-
threshold information centres will be assumed by the centres of expertise and units for rare 
diseases. The information will have been collected in cooperation with patient organisations 
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and the entire health, social and habilitation service network. It will cover all these areas 
extensively. Information will also be available electronically from a data bank collected by the 
centre and through helplines. Centre of expertise specialists will visit peer support groups for 
people with a rare disease to distribute and receive information. A reciprocal attitude is 
important to ensure that people with a rare disease and their families have sufficient 
possibilities for participating in developing care, habilitation and services. In other words, 
people with a rare disease and their families must be involved in producing experiential 
knowledge. This knowledge will also be drawn upon in teaching modules on rare diseases 
intended for health care professionals. 
Patient organisations are a key channel of influence for people with a rare disease and their 
families. They are federations that produce many types of services. Their members include 
associations for rare diseases and other patient organisations. Their role in preparing, 
developing and evaluating services is not adequate, as there is no clear model for their 
participation. Currently, adequate information about the effectiveness of cooperation with 
patient organisations at the level of university hospitals is lacking, and the first step would 
thus be studying this area. 
 
Patient organisation participation should be realised at three different levels:  
1) When centres of expertise are being set up, NGO representatives will be involved 
in the planning processes. 
2) Client panels, in which NGOs are involved, will evaluate the operation of centres 
of expertise and propose improvements. 
3) The forum for rare diseases maintained by the national coordinating centre for rare 
diseases will have broad-based representation of patient organisations. The board 
of the national centre will also have adequate numbers of NGO representatives 
(from several organisations, as the patients' situations vary according to the 
diagnosis group). 
 
In addition, the roles of the National Council on Disability and the Advisory Board for 
Rehabilitation in drafting issues related to rare diseases should be clarified to avoid 
overlapping efforts and to ensure that all possible expertise can be harnessed in the planning of 
service pathways and centre of expertise operation. 
 
Objectives: 
 People with a rare disease, their families and professionals will be provided with 
adequate information about social and health care services. 
 People with a rare disease and their families will have more involvement in the 
planning of service pathways. 
 Patient organisations will have better possibilities of exerting influence on the 
development of service structures. 
 Patient organisations will be involved in launching, evaluating and developing the 
operation of centres of expertise. 
 Patient organisations will participate in evaluating and developing services in the 
field of rare diseases. 
 
Indicators: Information obtained by people with a rare disease and their families about existing 
social and health services (patient survey); Participation of patient organisation representatives 
in the working group for planning the centres of expertise, the national forum for rare diseases, 
the board of the national coordinating centre for rare diseases and the centre of expertise client 
panels. 
37 
 
 
 
Responsible actors: National coordinating centre for rare diseases: Coordination of 
information activities, establishment of the national forum and the board of the national centre, 
preparation and designation of centres of expertise; Centres of expertise: customer panel 
 
Timeline: 2015−2017 
 
Prerequisites: No obstacles; regarding centres of expertise, the establishment of the centres 
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4 NATIONAL PLAN COORDINATION, 
 MONITORING AND EVALUATION 
 
The first action to be implemented under the Finnish National Plan for Rare Diseases is 
establishing a national coordinating centre for rare diseases. The steering group proposes that 
this should go ahead at the very beginning of the plan period, as the centre will coordinate the 
implementation of other National Plan actions. In order to establish this centre, the Ministry of 
Social Affairs and Health must take action and authorise the centre to coordinate National 
Plan implementation. As other priority measures of the programme, the steering group 
proposes acknowledging the special measures required by rare diseases in legislation, 
clarifying the care pathway for people with a rare disease, establishing units for rare diseases 
in university hospitals, promoting the availability and reimbursement of orphan drugs, and 
developing social support and habilitation. 
The operation of the national centre will be influenced by the national forum for rare 
diseases, in which university hospitals, patient organisations, municipal social services and the 
Social Insurance Institution will be represented. The forum will facilitate dialogue between 
stakeholders and direct and evaluate National Plan implementation. The activities of the forum 
will be organised by the national centre. The forum will meet as necessary, however no less 
than once a year, in connection with the seminar on rare diseases. 
The national centre will coordinate and monitor National Plan implementation, observing 
the timeline proposed for each action. In the event that it proves impossible to establish the 
national centre at the beginning of the plan period, the Ministry of Social Affairs and Health 
should appoint a temporary steering group to manage plan coordination. In 2014−2017, the 
National Plan for Rare Diseases will progress as follows: 
 
Year  National Plan for Rare diseases 
2014 Planning of National Plan implementation and capacity building  
2015 Plan implementation and mid-term evaluation 
2016 Plan implementation 
2017 
 
Final evaluation of the plan and planning of a new period 
 
 
Indicators for each action and key indicators drawn up by EUCERD will be used to 
evaluate National Plan implementation. In addition to EUCERD criteria, national indicators 
will be needed to facilitate monitoring and to gauge the effectiveness of planned actions. 
Developing these indicators will be one of the national centre's tasks. As there is little 
information available on the current status in many areas, assessing the impact of actions will 
be difficult. Consequently, the national centre should use any available means to analyse the 
current status of rare disease issues. Key themes in developing indicators will be feedback 
from professionals and patient organisations, delays in finding a diagnosis, changes in care 
practices, groups that fall through the cracks, integrity of care pathways and ensuring 
continuity of expertise. The satisfaction levels of people with a rare disease and their families 
should be surveyed at regular intervals. 
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The steering group proposes that a mid-term evaluation be carried out by the national 
coordinating centre for rare diseases in 2015 using EUCERD’s key indicators and the 
indicators specified for each action. In conjunction with the mid-term evaluation, the 
appropriateness of the selected indicators will be assessed, and the indicators will be 
developed further. At the end of the plan period in 2017, it would be justified to conduct an 
external evaluation which will be taken into account when setting the goals for the 
forthcoming plan period.  
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5 SUMMARY OF ACTIONS  
 
 
 
 Action Key content Objectives Obstacles /  
priorities 
1 Consistent 
definition of 
rare diseases 
and need for 
dedicated 
measures 
Adoption of EU definition of 
rare diseases; Acknowledg-
ment of the need for special 
measures in legislation 
Increasing EU level cooperation; 
Ensuring equal access to quality 
services 
Political support 
Priority 
2 Registry of rare 
diseases 
Creating a registry of rare 
diseases in Care Register for 
Health Care (Hilmo) based 
on the ICD-11 classification 
Facilitating the collection of 
research-based data; Increased 
cooperation both nationally and 
internationally 
Introduction of 
the ICD-11 
classification 
3 Research 
programme for 
rare diseases 
A share of national research 
funding allocated to research 
in rare diseases and the 
Finnish disease heritage; 
Submission to the Academy 
of Finland of a proposal for 
a multidisciplinary research 
programme on rare diseases  
Reinforcing research funding; 
Creating a network for scientific 
cooperation and a research 
database; Promoting research on 
service quality and on the impact 
and effectiveness of the service 
system 
Specifying the 
responsible actor 
4 Reinforcing 
international 
scientific  
cooperation 
Applying for membership of 
the E-RARE project 
Collection of sufficiently large 
patient data sets for clinical 
studies; Adequate research 
funding that enables participation 
in E-RARE 
Adequate 
national funding 
5 Clarification of 
the care 
pathway for 
people with a 
rare disease 
Streamlining the pathway 
aiming for the diagnosis and 
care of people with a rare 
disease, and dissemination 
of information on this; 
Development of a care 
passport 
Accelerate diagnosis and care 
delivery to people with a rare 
disease; Health care services at all 
levels will know how diagnostics 
and care are implemented; Care 
passports will facilitate the 
transfer of patients from one care 
facility to another and be useful in 
acute situations 
Establishment of 
units and centres 
of expertise for 
rare diseases; An 
electronic system 
for care passports 
Priority 
6 Setting up of 
units for rare 
diseases in 
university 
hospitals 
A unit for rare diseases will 
be set up in each university 
hospital with a rare diseases 
coordinator, a nurse and a 
multidisciplinary team 
Coordination of care and 
habilitation of patients requiring 
multidisciplinary competence; 
Horizontal cooperation will be 
facilitated; Smooth transition 
from paediatric to adult services; 
Safeguarding the possibility of 
working to improve diagnostics 
and care in the field of rare 
diseases 
Resource 
allocation in 
university 
hospitals 
Priority 
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 Action Key content Objectives Obstacles /  
priorities 
7 Establishing 
centres of 
expertise 
Centres of expertise for rare 
diseases meeting EU criteria 
and national centres of 
expertise will be established 
in Finland 
 
Centres of expertise share their 
expertise with all levels of the 
social welfare and health care 
system; Some centres have 
strategies for meeting the EU 
criteria 
Financial 
resources 
8 Education and 
training of 
professionals 
Social welfare and health 
care professionals will be 
provided with more 
education and training 
related to rare diseases 
Professionals dealing with rare 
diseases have up-to-date 
knowledge about rare diseases 
Universities' and 
polytechnics' 
approval for 
modification of 
education 
programmes 
9 Promoting the 
availability of 
orphan drugs 
The availability and 
reimbursement of drugs  
used to treat rare diseases 
will be promoted 
Availability of drugs will be 
safeguarded; Drugs eligible for 
reimbursement when used to treat 
a rare disease; Increased aware-
ness of the reimbursement system 
Legislative 
amendments 
concerning 
reimbursements 
Priority 
10 National 
coordinating 
centre for rare 
diseases 
A national coordinating 
centre for rare diseases will 
be set up 
Good governance and planning in 
the field of rare diseases; Syste-
matic collection of information on 
expertise in rare diseases in 
Finland; A forum for rare diseases 
meets regularly 
Financial 
resources 
Priority 
11 Collection and 
sharing of 
information 
A comprehensive database 
on rare diseases will be 
created; Information will be 
offered through a helpline; A 
seminar on rare diseases will 
be organised annually 
Information on rare diseases 
related to research, health care 
and social services and the 
support needed by people with a 
rare disease will be collected and 
offered systematically; Orphanet 
activities will be taken into 
account; Actors in the field of rare 
diseases will meet annually at a 
dedicated seminar 
No obstacles 
12 Development of 
social support 
and habilitation 
More information will be 
distributed about the 
services; Increasing the 
cooperation between various 
actors 
Closer cooperation between 
health care, social and habilitation 
services; Service plans for those 
requiring multidisciplinary 
competence; Availability of  
up-to-date information about 
habilitation and social services  
Appointment of a 
coordinating body 
Priority 
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 Action Key content Objectives Obstacles /  
priorities 
13 Empowerment 
of people with a 
rare disease 
People with a rare disease 
and patient organisations 
participate in decision-
making in the field of rare 
diseases and the planning of 
services  
Provision of adequate information 
about the services; Participation 
of people with a rare disease in 
planning service pathways; 
Patient organisations are able to 
influence the development of 
service structures; Patient 
associations will participate in the 
evaluation and development of 
services related to rare diseases 
No obstacles 
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ABBREVIATIONS 
 
 
ERC European Research Council 
EU  European Union 
EUCERD European Union Committee of Experts on Rare Diseases 
EUROPLAN European Project for Rare Diseases National Plans Development 
EURORDIS European Organisation for Rare Diseases 
Evo Special central government transfer 
Hilmo Care Register for Health Care  
HUS  Hospital District of Helsinki and Uusimaa 
HUCH Helsinki University Central Hospital 
ICD World Health Organisation classification system (International Statistical 
 Classification of Diseases) 
IRDiRC International Rare Diseases Research Consortium 
Kela Social Insurance Institution of Finland 
KYS Kuopio University Hospital 
OKM  Ministry of Education and Culture 
OYS Oulu University Hospital 
RAY Finland's Slot Machine Association 
STM Ministry of Social Affair and Health 
TAYS Tampere University Hospital 
THL  National Institute for Health and Welfare 
TYKS Turku University Central Hospital 
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APPENDIX 1 
 
COUNCIL OF THE EUROPEAN UNION 
RECOMMENDATION ON AN ACTION IN THE FIELD OF 
RARE DISEASES AND HOW IT IS TAKEN INTO 
ACCOUNT IN THE NATIONAL PLAN FOR RARE 
DISEASES  
 
COUNCIL RECOMMENDATION of 8 June 2009 on an action in the field of rare diseases  
(2009/C 151/02) 
 
 
 
THE COUNCIL OF THE EUROPEAN UNION RECOMMENDS THAT MEMBER 
STATES: 
 
I 
PLANS AND STRATEGIES IN THE FIELD OF RARE DISEASES 
1. Establish and implement plans or strategies for rare diseases at the appropriate level or 
explore appropriate measures for rare diseases in other public health strategies, in order to aim 
to ensure that patients with rare diseases have access to high-quality care, including 
diagnostics, treatments, habilitation for those living with the disease and, if possible, effective 
orphan drugs, and in particular: 
(a) elaborate and adopt a plan or strategy as soon as possible, preferably by the end of 2013 at 
the latest, aimed at guiding and structuring relevant actions in the field of rare diseases within 
the framework of their health and social systems; 
 Entire plan 
 
(b) take action to integrate current and future initiatives at local, regional and national levels 
into their plans or strategies for a comprehensive approach; 
 Action 10: A national coordinating centre for rare diseases 
 
(c) define a limited number of priority actions within their plans or strategies, with objectives 
and follow-up mechanisms;  
 Entire plan; priority actions are highlighted in the abstract and the Summary of 
Actions 
 
(d) take note of the development of guidelines and recommendations for the elaboration of 
national action for rare diseases by relevant authorities at national level in the framework of 
the ongoing European project for rare diseases national plans development (EUROPLAN) 
selected for funding over the period 2008-2011 in the first programme of Community action in 
the field of public health. 
 Entire plan         
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II 
ADEQUATE DEFINITION, CODIFICATION AND INVENTORYING OF 
RARE DISEASES  
2. Use for the purposes of Community-level policy work a common definition of rare disease 
as a disease affecting no more than 5 per 10 000 persons. 
 Action 1: Adopting a uniform definition of rare diseases 
 
3. Aim to ensure that rare diseases are adequately coded and traceable in all health information 
systems, encouraging an adequate recognition of the disease in the national healthcare and 
reimbursement systems based on the ICD while respecting national procedures. 
 Action 2: Registry of rare diseases 
 
4. Contribute actively to the development of the EU easily accessible and dynamic inventory 
of rare diseases based on the Orphanet network and other existing networks as referred to in 
the Commission Communication on rare diseases. 
 Action 11: Systematic collection and sharing of information  
 
5. Consider supporting at all appropriate levels, including the Community level, on the one 
hand, specific disease information networks and, on the other hand, for epidemiological 
purposes, registries and databases, whilst being aware of an independent governance. 
 Action 2: Registry of rare diseases 
 
 
III  
RESEARCH ON RARE DISEASES  
6. Identify ongoing research and research resources in the national and Community 
frameworks in order to establish the state of the art, assess the research landscape in the area 
of rare diseases, and improve the coordination of Community, national and regional 
programmes for rare diseases research.  
 Action 3: Research funding and a research programme focusing on rare diseases 
 Action 4: Building up international research cooperation 
 
7. Identify needs and priorities for basic, clinical, translational and social research in the field 
of rare diseases and modes of fostering them, and promote interdisciplinary co-operative 
approaches to be complementarily addressed through national and Community programmes. 
 Action 3: Research funding and a research programme focusing on rare diseases 
 
8. Foster the participation of national researchers in research projects on rare diseases funded 
at all appropriate levels, including the Community level. 
 Action 3: Research funding and a research programme focusing on rare diseases 
 Action 4: Building up international research cooperation 
 
9. Include in their plans or strategies provisions aimed at fostering research in the field of rare 
diseases.  
 Action 3: Research funding and a research programme focusing on rare diseases 
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Action 4: Building up international research cooperation 
 
10. Facilitate, together with the Commission, the development of research cooperation with 
third countries active in research on rare diseases and more generally with regard to the 
exchange of information and the sharing of expertise. 
 Action 4: Building up international research cooperation 
 
 
IV  
CENTRES OF EXPERTISE AND EUROPEAN REFERENCE NETWORKS 
FOR RARE DISEASES  
11. Identify appropriate centres of expertise throughout their national territory by the end of 
2013, and consider supporting their creation. 
 Action 6: Units for rare diseases in university hospitals 
Action 7: Centres of expertise for rare diseases 
 
12. Foster the participation of centres of expertise in European reference networks respecting 
the national competences and rules with regard to their authorisation or recognition. 
 Action 7: Centres of expertise for rare diseases 
 
13. Organise healthcare pathways for patients suffering from rare diseases through the 
establishment of cooperation with relevant experts and exchange of professionals and 
expertise within the country or from abroad when necessary. 
 Action 5: Clarification of the care pathway for people with a rare disease 
Action 6: Units for rare diseases in university hospitals 
Action 7: Centres of expertise for rare diseases 
 
14. Support the use of information and communication technologies such as telemedicine 
where it is necessary to ensure distant access to the specific healthcare needed. 
 Action 5: Clarification of the care pathway for people with a rare disease 
Action 6: Units for rare diseases in university hospitals 
Action 7: Centres of expertise for rare diseases 
 
15. Include, in their plans or strategies, the necessary conditions for the diffusion and mobility 
of expertise and knowledge in order to facilitate the treatment of patients in their proximity. 
 Action 5: Clarification of the care pathway for people with a rare disease 
Action 11: Systematic collection and sharing of information 
 
16. Encourage centres of expertise to be based on a multidisciplinary approach to care when 
addressing rare diseases.  
 Action 7: Centres of expertise for rare diseases 
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V  
GATHERING THE EXPERTISE ON RARE DISEASES AT EUROPEAN 
LEVEL  
17. Gather national expertise on rare diseases and support the pooling of that expertise with 
European counterparts in order to support:  
(a) the sharing of best practices on diagnostic tools and medical care as well as education and 
social care in the field of rare diseases; 
 Action 10: A national coordinating centre for rare diseases 
Action 11: Systematic collection and sharing of information 
 
(b) adequate education and training for all health professionals to make them aware of the 
existence of these diseases and of resources available for their care; 
 Action 8: Providing more education and training 
 
(c) the development of medical training in fields relevant to the diagnosis and management of 
rare diseases, such as genetics, immunology, neurology, oncology or paediatrics; 
 Action 8: Providing more education and training 
 
(d) the development of European guidelines on diagnostic tests or population screening, while 
respecting national decisions and competences;  
 
(e) the sharing Member States′ assessment reports on the therapeutic or clinical added value of 
orphan drugs at Community level where the relevant knowledge and expertise is gathered, in 
order to minimise delays in access to orphan drugs for rare disease patients. 
 Action 9: Promoting the availability of orphan drugs 
 
 
VI  
EMPOWERMENT OF PATIENT ORGANISATIONS  
18. Consult patients and patients′ representatives on the policies in the field of rare diseases 
and facilitate patient access to updated information on rare diseases. 
 Action 13: Empowerment of people with a rare disease 
 
19. Promote the activities performed by patient organisations, such as awareness-raising, 
capacity-building and training, exchange of information and best practices, networking and 
outreach to very isolated patients.  
 Action 13: Empowerment of people with a rare disease 
 
 
VII  
SUSTAINABILITY  
20. Together with the Commission, aim to ensure, through appropriate funding and 
cooperation mechanisms, the long-term sustainability of infrastructures developed in the field 
of information, research and healthcare for rare diseases. 
 Entire plan 
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APPENDIX 2 
 
 
EUCERD RECOMMENDATIONS ON QUALITY CRITERIA 
FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN 
MEMBER STATES  
 
 Capacity to produce and adhere to good practice guidelines for diagnosis and care. 
 Quality management in place to assure quality of care, including National and 
European legal provisions, and participation in internal and external quality schemes 
when applicable. 
 Capacity to propose quality of care indicators in their area and implement outcome 
measures including patient satisfaction. 
 High level of expertise and experience documented, for instance, by the annual 
volume of referrals and second opinions, and through peer-reviewed publications, 
grants, positions, teaching and training activities. 
 Appropriate capacity to manage rare disease (RD) patients and provide expert advice. 
 Contribution to state-of-the-art research. 
 Capacity to participate in data collection for clinical research and public health 
purposes. 
 Capacity to participate in clinical trials, if applicable.  
 Demonstration of a multi-disciplinary approach, when appropriate, integrating 
medical, paramedical, psychological and social needs (e.g. RD board). 
 Organisation of collaborations to assure the continuity of care between childhood, 
adolescence and adulthood, if relevant. 
 Organisation of collaborations to assure the continuity of care between all stages of 
the disease. 
 Links and collaboration with other centres of expertise at national, European and 
international level. 
 Links and collaboration with patient organisations where they exist. 
 Appropriate arrangements for referrals within individual Member States and from/to 
other EU countries if applicable. 
 Appropriate arrangements to improve the delivery of care and especially to shorten 
the time taken to reach a diagnosis. 
 Consideration of eHealth solutions (e.g. shared case management systems, expert 
systems for tele-expertise and shared repository of cases). 
 
 
 
